A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Lilly ICOS
- 07 Aug 2019 This trial was completed in United Kingdom (end date:2007-08-16), according to European Clinical Trials Database.
- 26 Jun 2019 This trial has been completed in Ireland, according to European Clinical Trials Database.
- 18 Jul 2014 New trial record